ArticleScientific reports2026
Investigating serum free light chains in patients with common variable immunodeficiency disorder in compare with other immunodeficiency diseases.
Article in Scientific reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
13 authors.
Funding
Abstract
Serum free light chains (sFLCs) have recently been introduced as a diagnostic biomarker in common variable immunodeficiency (CVID) patients. Most patients with CVID have undetectable or lower levels of sFLCs compared to people with other types of immune system deficiencies with hypogammaglobulinemia, except for patients with agammaglobulinemia (AGG). Decreased production of kappa (κ) and lambda (λ) light chains over immunoglobulins (Ig) suggests a malfunction in early B cell development or plasma cell dysfunction may cause CVID. In this cross-sectional study, immunoturbidimetry was used to measure sFLCs in 70 immunodeficiency patients, including 39 patients with CVID, 31 patients with other immunodeficiencies with hypogammaglobulinemia such as combined immunodeficiency (CID), AGG, and other primary immunodeficiencies (PIDs), and 20 healthy controls. The levels of both κ and λ chains were significantly higher in patients with CID than patients with CVID and AGG patients (p < 0.05). The median (Q1–Q3) κ level in patients with other primary immunodeficiency disorders (PIDs) was significantly higher than that observed in patients with AGG and CVID (p < 0.01). Similarly, the median (Q1–Q3) λ level was higher in patients with other PIDs compared with those with AGG and CVID (p < 0.05).ROC analysis of κ and λ disclosed an area under the curve (AUC) for κ was 0.98 (95% CI: 0.96–0.99, p < 0.0001) and for λ was 0.95 (95% CI: 0.89–0.99, p < 0.0001) in patients with CVID. The sFLCs test can help distinguish between CVID and other immunodeficiency patients with hypogammaglobulinemia and the diagnosis of hypogammaglobulinemia.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.